Lataa...
The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk.
PURPOSE OF REVIEW: Direct-acting antiviral agents (DAAs) eradicate hepatitis C virus (HCV) infection in the majority of patients. We critically evaluated the impact of DAAs on hepatocellular carcinoma (HCC) risk, a major complication of HCV infection. RECENT FINDINGS: Large cohort studies show that...
Tallennettuna:
| Julkaisussa: | Curr Hepatol Rep |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6433385/ https://ncbi.nlm.nih.gov/pubmed/30923667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11901-018-0424-8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|